Grunenthal GmbH - Company Profile
Powered by 
All the data and insights you need on Grunenthal GmbH in one report.
$295
- Save hours of research time and resources with
our up-to-date Grunenthal GmbH Strategy Report
- Understand Grunenthal GmbH position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company that researches, develops and markets products for the treatment of pain management and related diseases. Its portfolio includes a wide range of medicinal products for chronic and acute pain, nociceptive and neuropathic pain. The company’s products portfolio include Tramal used for the treatment of moderate to severe pain; Transtec used to treat moderate to severe cancer pain; and Vimovo used for the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The company distributes products and operates in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Nordrhein-Westfalen, Germany.
Headquarters
Germany
Address
Zieglerstrasse 6, Aachen, Nordrhein-Westfalen, 52078
Website
www.grunenthal.com
Telephone
49 241 5690
No of Employees
4,431
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$1.7B
Grunenthal GmbH premium industry data and analytics
Products and Services
| Products |
|---|
| Versatis - for Neuropathic Pain |
| Nucynta - for Acute and Chronic Pain |
| Qutenza - for Peripheral Neuropathic Pain in Adults |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company and Kyowa Kirin Co Ltd formed a joint venture collaboration for Kyowa Kirin International's established medicines portfolio. |
| 2023 | Contracts/Agreements | In April, the company and King's College London entered into a partnership to develop microfluidic culture models based on human induced pluripotent stem cells and tailored to pain research. |
| 2022 | Acquisitions/Mergers/Takeovers | In November, the company acquired rights to Nebido from Bayer. |
Competitor Comparison
| Key Parameters | Grunenthal GmbH | Mibe GmbH Arzneimittel | TAD Pharma GmbH | Mundipharma International Ltd | Endo Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Germany | Germany | Germany | United Kingdom | United States of America |
| City | Aachen | Brehna | Cuxhaven | Cambridge | Chester |
| State/Province | Nordrhein-Westfalen | Sachsen-Anhalt | Niedersachsen | England | Pennsylvania |
| No. of Employees | 4,431 | 427 | 320 | 120 | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gabriel Baertschi | Chief Executive Officer | Senior Management | - | 49 |
| Fabian Raschke | Chief Financial Officer | Senior Management | 2019 | 46 |
| Jan Adams, MD | Chief Scientific Officer | Senior Management | 2020 | 46 |
| Janneke van der Kamp | Chief Commercial Officer | Senior Management | - | 48 |
| Par Johansson | Chairman | Non Executive Board | - | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer